Galecto

Historical price data

Galecto's mission is to develop transformative therapeutics for fibrosis, inflammation, and cancer by selectively inhibiting galectin proteins, central mediators of these disease processes. Its key achievement is advancing its lead oral galectin-3 inhibitor, GB1211, into Phase 2 trials for liver fibrosis and Phase 1b/2 for oncology combinations. The company's strategy is to generate robust clinical proof-of-concept data in these serious conditions to unlock significant value. Galecto operates as a focused, platform-based entity, aiming to demonstrate the broad therapeutic potential of its galectin-targeting approach.

Proprietary platform for the discovery and development of selective, oral small-molecule inhibitors of galectin proteins, particularly galectin-3, targeting central pathways in fibrosis, inflammation, and cancer.

In MASH, Galecto differentiates via a direct anti-fibrotic mechanism targeting galectin-3, competing against agents focused on metabolic drivers. In oncology, it competes in the crowded ICI combination space but with a niche focus on the galectin-3 immunosuppressive axis. Success hinges on demonstrating superior or complementary efficacy/safety.